EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study

Ayako Shiono iD, Hisao Imai iD, Kyoichi Kaira iD, Takanori Abe iD, Yuki Sato, Ken Yamamoto iD, Hiroki Watanabe, Yuko Tsuchiya-Kawano, Akihiro Tamiya, Takashi Osaki, Noriko Yanagitani, Shigeru Tanzawa und 11 weitere

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Ayako Shiono und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Platinum, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Main Problem The efficacy and safety of platinum‐based chemotherapy with programmed death‐1 (PD‐1) blockade after chemoradiotherapy (CRT) for the treatment of limited disease (LD) small cell lung cancer (SCLC) is unknown. This study aimed to assess the effectiveness and tolerability of platinum‐based chemotherapy with PD‐1 blockade in patients with recurrent LD‐SCLC after CRT.

Methods

This retrospective study analyzed 66 patients who experienced recurrence after CRT for LD‐SCLC and received platinum‐based chemotherapy with PD‐1 blockade therapy between August 2019 and September 2020 at 19 Japanese institutions. Clinical efficacy was assessed according to response rate, survival, and toxicity.

Results

The overall response rate was 53.0% (95% confidence interval [CI], 48.9–65.0), and the disease control rate was 78.7% (95% CI, 68.9–88.5). The median progression‐free survival and overall survival periods were 5.9 (95% CI, 4.7–7.3) months and 24.9 (95% CI, 16.8–28.1) months, respectively. The frequencies of grade ≥ 3 hematological adverse events were as follows: leukopenia, 47.0%; neutropenia, 65.2%; and febrile neutropenia, 8.3%. There was no treatment‐related death.

Conclusions

Chemoimmunotherapy is a feasible and effective treatment for recurrent disease after CRT in patients with LD‐SCLC, providing a new potential option for the pharmacological management of these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsPlatinumAntineoplastic Combined Chemotherapy ProtocolsProgrammed Cell Death 1 ReceptorHumansMaleRetrospective StudiesFemaleAgedMiddle AgedAdultAged, 80 and over

Stichwörter der Autor:innen

PD‐1 blockadechemoradiotherapylimited disease small cell lung cancerrecurrenceretrospective

Substanzen

PlatinumProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Gunma, Japan.
  • Department of Radiation Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
  • Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Hyogo, Japan.
  • Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Niigata, Japan.

ORCID-Profile: Ayako Shiono, Hisao Imai, Kyoichi Kaira, Takanori Abe, Ken Yamamoto, Toshiyuki Sumi, Shinnosuke Takemoto, Yoshiaki Nagai

Zitieren

APA

Shiono, A., Imai, H., Kaira, K., Abe, T., Sato, Y., Yamamoto, K., Watanabe, H., Tsuchiya-Kawano, Y., Tamiya, A., Osaki, T., Yanagitani, N., Tanzawa, S., Sumi, T., Yoshimine, K., Matsui, Y., Endo, S., Shibata, K., Takemoto, S., Miura, Y., …, & Kagamu, H. (2025). Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70118

Vancouver

Shiono A, Imai H, Kaira K, Abe T, Sato Y, Yamamoto K, et al. Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70118

BibTeX
@article{Shiono2025,
  author = {Shiono, Ayako and Imai, Hisao and Kaira, Kyoichi and Abe, Takanori and Sato, Yuki and Yamamoto, Ken and Watanabe, Hiroki and Tsuchiya-Kawano, Yuko and Tamiya, Akihiro and Osaki, Takashi and Yanagitani, Noriko and Tanzawa, Shigeru and Sumi, Toshiyuki and Yoshimine, Kohei and Matsui, Yohei and Endo, Satoshi and Shibata, Kazuhiko and Takemoto, Shinnosuke and Miura, Yosuke and Nagai, Yoshiaki and Nakagawa, Junichi and Tsuda, Takeshi and Kagamu, Hiroshi},
  title = {Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70118}
}
Kostenlos starten →